Investors to Gain Insight on TERN-701 in Upcoming Webinar
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative small-molecule therapies for serious health conditions, is set to host an informative webinar focused on TERN-701. This event aims to shed light on the promising developments surrounding TERN-701 ahead of crucial Phase 1 data anticipated in the later part of 2025.
What is TERN-701?
TERN-701 is an investigational treatment designed as a next-generation oral allosteric BCR-ABL inhibitor. This novel drug specifically targets the ABL myristoyl pocket, a critical area for the treatment of chronic myeloid leukemia (CML). CML is a type of cancer that affects the blood and bone marrow and is characterized by the overproduction of myeloid cells.
Webinar Features and Details
The upcoming educational session will feature discussions led by key figures within Terns Pharmaceuticals, including Amy Burroughs (CEO), Emil Kuriakose, M.D. (CMO), and Scott Harris (CDO). They will provide insights into TERN-701's potential as a best-in-class candidate, benchmarks for the Phase 1 data, and its prospective role within a changing treatment paradigm for CML.
Scheduled Webinar Information
Date: September 3, 2025
Time: 4:30 PM ET
Details on how to register will be shared closer to the date, ensuring participants can easily access this vital information.
About CARDINAL Phase 1 Clinical Trial
TERN-701 is currently being evaluated through the CARDINAL clinical trial, which is a global, multi-center study aimed at assessing the safety, tolerability, and effectiveness of this treatment in patients with previously treated chronic phase CML. Significant milestone updates have indicated that the initial dose escalation phase, which concluded in January 2025, did not present any dose-limiting toxicities at a maximum dosage of 500 mg, making it a promising candidate.
Patient Cohorts and Results
Following the successful dose escalation phase, Terns Pharmaceuticals began the dose expansion segment in April 2025, engaging patients in randomized groups at doses of either 320 mg or 500 mg. As the trial progresses, data on efficacy and safety will be expected in the fourth quarter of 2025, specifically focusing on the six-month major molecular response achievements.
Company's Commitment to Innovation
Terns Pharmaceuticals is committed to advancing health through biotechnology, bringing forth several clinical-stage programs designed to target serious diseases, including conditions associated with oncology and obesity. Their carefully curated pipeline also includes other promising compounds such as a small-molecule GLP-1 receptor agonist and a THR-? agonist, reinforcing their dedication to tackling complex health challenges.
Company Contact Information
For any inquiries regarding the webinar or TERN-701, potential investors and interested parties can reach out to:
Investors Contact:
Justin Ng
Email: investors@ternspharma.com
Media Contact:
Jenna Urban
CG Life
Email: media@ternspharma.com
Frequently Asked Questions
What is the purpose of the upcoming webinar?
The webinar will provide insights into TERN-701's potential as a best-in-class therapy for chronic myeloid leukemia and upcoming clinical data.
Who will lead the discussion during the webinar?
The session will be led by Terns' executive team, including CEO Amy Burroughs, CMO Emil Kuriakose, M.D., and CDO Scott Harris.
What can participants expect from the clinical trial updates?
Attendees will receive information regarding the safety and efficacy data related to TERN-701, particularly focusing on the results from the Phase 1 trial.
How can interested individuals register for the webinar?
Details about registration for the webinar will be provided by Terns Pharmaceuticals ahead of the event date.
Where can I find more information on Terns Pharmaceuticals?
Additional information about the company and its research can be found on their official website.
